223 related articles for article (PubMed ID: 36546346)
21. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
Buhl T; Rosmarin D; Serra-Baldrich E; Fernandez-Peñas P; Igarashi A; Konstantinou MP; Chen S; Lu N; Pierce E; Casillas M
Dermatol Ther (Heidelb); 2021 Jun; 11(3):971-982. PubMed ID: 33899152
[TBL] [Abstract][Full Text] [Related]
22. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
Torrelo A; Rewerska B; Galimberti M; Paller A; Yang CY; Prakash A; Zhu D; Pontes Filho MAG; Wu WS; Eichenfield LF
Br J Dermatol; 2023 Jul; 189(1):23-32. PubMed ID: 36999560
[TBL] [Abstract][Full Text] [Related]
24. Infectious adverse events in patients with atopic dermatitis treated with baricitinib.
Antonelli F; Malvaso D; Caldarola G; Simone C; Peris K; Chiricozzi A
Immunotherapy; 2023 Dec; 15(18):1521-1529. PubMed ID: 37850366
[TBL] [Abstract][Full Text] [Related]
25. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
Mod Rheumatol; 2020 Jan; 30(1):36-43. PubMed ID: 30784354
[No Abstract] [Full Text] [Related]
26. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials.
Wollenberg A; Lio P; Kleyn E; Bissonnette R; Jose Rueda M; Casillas M; Chen YF; Lu N; Schloebe A; Simpson E
Eur J Dermatol; 2022 Jul; 32(4):522-529. PubMed ID: 36301752
[TBL] [Abstract][Full Text] [Related]
27. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.
Genovese MC; Smolen JS; Takeuchi T; Burmester G; Brinker D; Rooney TP; Zhong J; Daojun M; Saifan C; Cardoso A; Issa M; Wu WS; Winthrop KL
Lancet Rheumatol; 2020 Jun; 2(6):e347-e357. PubMed ID: 38273598
[TBL] [Abstract][Full Text] [Related]
28. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Winthrop KL; Harigai M; Genovese MC; Lindsey S; Takeuchi T; Fleischmann R; Bradley JD; Byers NL; Hyslop DL; Issa M; Nishikawa A; Rooney TP; Witt S; Dickson CL; Smolen JS; Dougados M
Ann Rheum Dis; 2020 Oct; 79(10):1290-1297. PubMed ID: 32788396
[TBL] [Abstract][Full Text] [Related]
29. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL; Lacour JP; Spelman L; Galimberti R; Eichenfield LF; Bissonnette R; King BA; Thyssen JP; Silverberg JI; Bieber T; Kabashima K; Tsunemi Y; Costanzo A; Guttman-Yassky E; Beck LA; Janes JM; DeLozier AM; Gamalo M; Brinker DR; Cardillo T; Nunes FP; Paller AS; Wollenberg A; Reich K
Br J Dermatol; 2020 Aug; 183(2):242-255. PubMed ID: 31995838
[TBL] [Abstract][Full Text] [Related]
30. Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Taylor PC; Bieber T; Alten R; Witte T; Galloway J; Deberdt W; Issa M; Haladyj E; De La Torre I; Grond S; Wollenberg A
Adv Ther; 2023 Apr; 40(4):1867-1883. PubMed ID: 36802049
[TBL] [Abstract][Full Text] [Related]
31. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.
Thyssen JP; Bieber T; Kleyn CE; Nosbaum A; Grond S; Petto H; Riedl E; Wollenberg A
J Dermatolog Treat; 2023 Dec; 34(1):2216322. PubMed ID: 37345379
[TBL] [Abstract][Full Text] [Related]
32. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
Simpson EL; Bissonnette R; Paller AS; King B; Silverberg JI; Reich K; Thyssen JP; Doll H; Sun L; DeLozier AM; Nunes FP; Eichenfield LF
Br J Dermatol; 2022 Oct; 187(4):531-538. PubMed ID: 35442530
[TBL] [Abstract][Full Text] [Related]
33. Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.
Chen YC; Yoo DH; Lee CK; Li KJ; Won JE; Wu WS; Zhong J; Nicolay C; Walls CD; Tanaka Y
Int J Rheum Dis; 2020 Jan; 23(1):65-73. PubMed ID: 31729189
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis.
Bridgeman SG; Martino AK; Strowd LC
Expert Opin Pharmacother; 2023; 24(18):2153-2159. PubMed ID: 38018382
[TBL] [Abstract][Full Text] [Related]
35. Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes.
Simpson E; Armstrong A; Boguniewicz M; Chiesa Fuxench ZC; Feely M; Pierce E; Sun L; Chen YF; Angle R; Silverberg JI
Dermatol Ther; 2022 Dec; 35(12):e15954. PubMed ID: 36270978
[TBL] [Abstract][Full Text] [Related]
36. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract][Full Text] [Related]
37. Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients.
Radi G; Simonetti O; Rizzetto G; Diotallevi F; Molinelli E; Offidani A
Healthcare (Basel); 2021 Nov; 9(11):. PubMed ID: 34828623
[No Abstract] [Full Text] [Related]
38. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
Stein Gold L; Thaçi D; Thyssen JP; Gooderham M; Laquer V; Moore A; Natalie CR; Zhao F; Meskimen E; Elmaraghy H; Montmayeur S; Gallo G; Jimenez G; de Bruin-Weller M
Am J Clin Dermatol; 2023 Jul; 24(4):595-607. PubMed ID: 37195407
[TBL] [Abstract][Full Text] [Related]
39. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
Wollenberg A; Nakahara T; Maari C; Peris K; Lio P; Augustin M; Silverberg JI; Rueda MJ; DeLozier AM; Pierce E; Yang FE; Sun L; Ball S; Tauber M; Paul C
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1543-1552. PubMed ID: 33834521
[TBL] [Abstract][Full Text] [Related]
40. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
Silverberg JI; Boguniewicz M; Waibel J; Weisman J; Strowd L; Sun L; Ding Y; Feely M; Nunes FP; Simpson EL
Dermatol Ther (Heidelb); 2022 Jan; 12(1):137-148. PubMed ID: 34846636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]